| 27.83 0.09 (0.32%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.43 | 1-year : | 36.16 |
| Resists | First : | 29.48 | Second : | 30.95 |
| Pivot price | 28.77  |
|||
| Supports | First : | 27.1 | Second : | 22.54 |
| MAs | MA(5) : | 27.77 |
MA(20) : | 28.91 |
| MA(100) : | 24.76 |
MA(250) : | 24.1 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 15.2 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 30.95 | Low : | 19.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACAD ] has closed above bottom band by 23.9%. Bollinger Bands are 23% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.26 - 28.37 | 28.37 - 28.48 |
| Low: | 27.44 - 27.57 | 27.57 - 27.71 |
| Close: | 27.62 - 27.82 | 27.82 - 28.02 |
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Fri, 11 Sep 2026
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Fri, 11 Sep 2026
Acadia Pharmaceuticals announces preliminary court approval of settlement in stockholder derivative action - Investing.com
Fri, 11 Sep 2026
ACADIA PHARMACEUTICALS INC Reports Material Event - Stock Titan
Mon, 24 Aug 2026
ACADIA Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD) - Seeking Alpha
Sat, 08 Aug 2026
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Fri, 07 Aug 2026
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 172 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 99.8 (%) |
| Shares Short | 9,480 (K) |
| Shares Short P.Month | 11,030 (K) |
| EPS | 2.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.59 |
| Profit Margin | 33.4 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 3.6 % |
| Return on Equity (ttm) | 35.7 % |
| Qtrly Rev. Growth | 16.3 % |
| Gross Profit (p.s.) | 4.1 |
| Sales Per Share | 6.61 |
| EBITDA (p.s.) | 0.57 |
| Qtrly Earnings Growth | 13.3 % |
| Operating Cash Flow | 160 (M) |
| Levered Free Cash Flow | 69 (M) |
| PE Ratio | 12.47 |
| PEG Ratio | 50.8 |
| Price to Book value | 3.66 |
| Price to Sales | 4.2 |
| Price to Cash Flow | 29.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|